This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover and develop new, more potent antifungal therapies for treating invasive fungal infections such as cryptococcosis, candidiasis, and aspergillosis. The funding will support the continued screening of chemical libraries to identify lead compounds that selectively inhibit the fungal ceramide synthase 1...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $616,588 to The Regents of the University of California, San Francisco (UCSF) over a 5-year period from June 2025 to May 2030. The grant will support research to identify and study new components of key pathways related to environmental sensing mechanisms in the fungal pathogen Cryptococcus neoformans,...
This $232,073 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 (Allergy and Infectious Diseases Research) aims to explore the phenomenon of replicative aging in the opportunistic fungal pathogen Cryptococcus neoformans (CN) and its implications during co-infection with HIV in AIDS patients. The research will investigate the host-pathogen dynamics between CN, HIV, and microglia, the predominant brain-resident macrophages, to understand...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of novel antifungal therapeutics targeting the glycosylphosphatidylinositol (GPI) biosynthesis pathway. The $170,000 award to Prokaryotics Incorporated will fund structural biology studies to elucidate the molecular interactions between the natural product M743 and the fungal GPI biosynthesis...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $773,053 to The Washington University to conduct research on the biosynthesis of beta-1,6-glucan, a key component of the Cryptococcus neoformans cell wall. The research aims to elucidate the role of the GGT2 glycosyltransferase in beta-1,6-glucan formation and identify other proteins involved in the synthesis of this...
This federal Project Grant award of $857,215 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate how the fungal pathogen Candida albicans adapts its acetylome, or acetylation patterns, to survive in different host environments during oral and invasive infections. The research aims to identify C. albicans GCN5 (a lysine acetyltransferase) target proteins that are acetylated...
The University of Southern California (USC) received a $623,986 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The funding supports a research project to study the genetic and molecular mechanisms that enable fungi, specifically the opportunistic pathogen Saccharomyces cerevisiae, to persist and cause infections in mammalian hosts. Key objectives include: Identifying causal...
This $158,433 federal Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify the mechanisms that allow the pathogenic fungus Cryptococcus neoformans to tolerate high levels of carbon dioxide as a requirement for virulence. The research objectives are to define the metabolic profile induced by carbon dioxide stress across diverse Cryptococcus isolates,...
This $233,670 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to determine the genetic mechanisms underlying skin colonization by the emerging fungal pathogen Candida auris. The University of Michigan, the awardee, will leverage its established in vitro and in vivo models to investigate clade-specific differences in C. auris adhesion and skin...
This $838,320 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) funds research to define the genetic determinants of Aspergillus fumigatus pathogenicity in the context of Bruton's tyrosine kinase (BTK) inhibitor cancer therapies. The research aims to uncover novel fungal factors that enable invasive aspergillosis in patients receiving BTK inhibitor treatments, which have been...